Celcuity Inc. (NASDAQ:CELC) Given Consensus Rating of “Buy” by Analysts

Shares of Celcuity Inc. (NASDAQ:CELC) have earned an average recommendation of “Buy” from the seven ratings firms that are presently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $30.17.

A number of research firms have commented on CELC. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Celcuity in a research note on Friday, November 15th. Needham & Company LLC upped their price objective on shares of Celcuity from $23.00 to $29.00 and gave the company a “buy” rating in a report on Thursday, February 6th.

Celcuity Stock Performance

Shares of CELC opened at $12.41 on Friday. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. The firm has a market cap of $460.78 million, a PE ratio of -4.75 and a beta of 0.73. Celcuity has a 12 month low of $10.35 and a 12 month high of $22.19. The stock has a fifty day moving average price of $12.27 and a 200-day moving average price of $14.24.

Hedge Funds Weigh In On Celcuity

Several hedge funds and other institutional investors have recently bought and sold shares of CELC. BNP Paribas Financial Markets lifted its stake in Celcuity by 2,083.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 45,110 shares of the company’s stock valued at $673,000 after acquiring an additional 43,044 shares during the period. Geode Capital Management LLC lifted its position in Celcuity by 27.6% during the third quarter. Geode Capital Management LLC now owns 630,369 shares of the company’s stock valued at $9,401,000 after purchasing an additional 136,518 shares during the period. State Street Corp lifted its position in Celcuity by 152.2% during the third quarter. State Street Corp now owns 1,107,415 shares of the company’s stock valued at $16,512,000 after purchasing an additional 668,318 shares during the period. Braidwell LP boosted its holdings in Celcuity by 71.2% in the third quarter. Braidwell LP now owns 884,306 shares of the company’s stock valued at $13,185,000 after purchasing an additional 367,663 shares during the last quarter. Finally, Barclays PLC grew its position in Celcuity by 567.6% during the 3rd quarter. Barclays PLC now owns 53,605 shares of the company’s stock worth $800,000 after purchasing an additional 45,576 shares during the period. Institutional investors and hedge funds own 63.33% of the company’s stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.